The findings underscore the importance of maintaining a stable Hb concentration within the target range to reduce the risk of mortality and morbidity in patients with NDD-CKD while highlighting the suboptimal and heterogeneous treatment of anemia in clinical practice. The gene discussed is GSTM1; the disease is anemia.